Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
Medtronic
McKinsey
Moodys
Boehringer Ingelheim

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for LY3023414

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for LY3023414?

LY3023414 is an investigational drug.

There have been 16 clinical trials for LY3023414. The most recent clinical trial was a Phase 1 trial, which was initiated on September 1st 2015.

The most common disease conditions in clinical trials are Neoplasms, Carcinoma, Non-Small-Cell Lung, and Nervous System Neoplasms. The leading clinical trial sponsors are Eli Lilly and Company, National Cancer Institute (NCI), and SCRI Development Innovations, LLC.

There are two US patents protecting this investigational drug and forty-two international patents.

Recent Clinical Trials for LY3023414
TitleSponsorPhase
Treatment With Oral LY3023414 To Inhibit Homologous Recombination Followed By PrexasertibEli Lilly and CompanyPhase 2
Treatment With Oral LY3023414 To Inhibit Homologous Recombination Followed By PrexasertibBaylor Research InstitutePhase 2
A Phase 2 Study of LY3023414 and Abemaciclib With or Without Letrozole in Endometrial CancerEli Lilly and CompanyPhase 2

See all LY3023414 clinical trials

Clinical Trial Summary for LY3023414

Top disease conditions for LY3023414
Top clinical trial sponsors for LY3023414

See all LY3023414 clinical trials

US Patents for LY3023414

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
LY3023414   Start Trial PI3 kinase/mTOR dual inhibitor Eli Lilly and Company (Indianapolis, IN)   Start Trial
LY3023414   Start Trial PI3 kinase/mTOR dual inhibitor Eli Lilly and Company (Indianapolis, IN)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for LY3023414

Drugname Country Document Number Estimated Expiration Related US Patent
LY3023414 Argentina 084551 2031-01-14   Start Trial
LY3023414 Australia 2012205619 2031-01-14   Start Trial
LY3023414 Brazil 112013017672 2031-01-14   Start Trial
LY3023414 Canada 2824760 2031-01-14   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Moodys
McKesson
Merck
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.